With embryonic stem cells in clinical trials in the U.S. and the U.K., France looks to keep up.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
Technologies that can pull tumor cells from patients’ blood are giving researchers an unprecedented look at cancer.
Carrier screening can prevent disease in families, but some doubt that it can change population-level incidence of disease.
Monsanto and others look to RNA interference to fight widespread bee-killing mites.
DNA analysis continues its baby boom.
Patients with blindness caused by retinitis pigmentosa can now get a light-detecting microchip implanted in one of their retinas.
A mixture of three cell types self-assembles into a liver bud that can be seen with the naked eye.
Genetic material suitable for sequencing could persist for as many as one million years, predict scientists.
A thin probe of carbon nanotubes can measure small electrical changes inside a neuron.
The decision should reduce uncertainty in the field of molecular diagnostics.